INTRODUCTION
Interleukin 17 (IL-17) represents a family of proinflammatory cytokines consisting of six members, termed IL-17A-F. IL-17A is expressed by a unique lineage of CD4 T cells and is known to stimulate fibroblasts, endothelial cells, epithelial cells, and macrophages to produce multiple proinflammatory mediators, including IL-1, IL-6, tumor necrosis factor (TNF)-a, NOS-2, and chemokines, resulting in the induction of inflammation (Aggarwal et al., 2003; Onishi and Gaffen, 2010) . Previous studies have shown that IL-17 is actively involved in a range of pathologic conditions in humans, ranging from common asthma to several autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease, as well as allergen-specific immune responses (Iwakura and Ishigame, 2006 ; Kolls and Lindé n, 2004; Nakae et al., 2002) . The signaling of IL-17 in several cell types is mediated by binding to endogenous IL-17 receptors (IL-17R), a group comprising five receptor types, termed IL-17RA-IL-17RE (Aggarwal and Gurney, 2002) . Recently, it was shown that IL-17A signaling is mediated by a heteromeric complex containing IL-17RA and IL-17RC chains (Toy et al., 2006) . Both receptors are single $90 kDa transmembrane proteins and contain conserved structural motifs (Gaffen, 2009; Kramer et al., 2007) . The IL-17 receptors are not homologs to any known receptors and possess unique signaling properties, which enable Th-17 cells to act as a bridge between cells of the innate and adaptive immune systems (Ely et al., 2009) .
The roles of the IL-17A pathway in mediating inflammation and autoimmune disorders render it an attractive target for intervention. Blocking of IL-17A binding to its receptor may lead to the abolishment of downstream signaling effects and thus prevent various inflammatory disorders. A direct approach for targeting the IL-17A pathway would involve the use of antibodies or soluble IL-17RA that will bind IL-17A with high affinity, and thus prevent ligand binding to the endogenous receptor. In general, antibody-based therapeutics provide the advantage of a stable scaffold with high affinity and specificity to the target ligand. However, antibodies can bind the target ligand at sites that are remote or only partially overlap with the receptor binding site and thus compromise the ability of the antibody to prevent the endogenous ligand-receptor interaction. For example, the recognition of IL-17A by the antibody CAT-2200 only partially overlaps with the binding site of the IL-17RA for IL-17 (Gerhardt et al., 2009) (Figure S1 available online). In contrast, soluble receptors can effectively compete with the endogenous cell surface receptors for the native ligand binding site and provide a variety of scaffolds with different size, stability, and affinity.
In the past few years, directed evolution methodologies have proven to be highly valuable for generating proteins with improved functions. Directed evolution methodologies are based on the principles of natural Darwinian evolution and consist of two major steps: (i) creation of genetic diversity in the target gene in the form of gene libraries, and (ii) effective selection or screening of those libraries for the desired activity (Aharoni et al., 2005; Tao and Cornish, 2002) . Directed evolution has been employed for improving the catalytic activity of enzymes, for altering substrate specificity, for enhancing thermostability, and for augmenting expression in recombinant systems. In addition, this approach was used to generate proteins with significantly enhanced affinity for various ligands (Gai and Wittrup, 2007; Umetsu et al., 2010) .
In this work, we utilized directed evolution methodologies to generate IL-17RA extracellular domain (ECD) (Gaffen, 2009) variants that show high affinity for IL-17A, potent inhibition of IL-17-induced cytokine secretion from cells, and the inhibition of psoriasis plaque formation in a mouse model. We first generated a focused library of IL-17RA mutants incorporating diversity based on evolutionary information. The IL-17RA library was screened using yeast surface display (YSD), followed by ELISA screening of single mutants expressed in mammalian cells. Two improved IL-17RA variants exhibited higher affinity, thermostability, and inhibition of IL-17A-induced IL-6 and Gro-a secretion both in a cell line and in mice, relative to the wild-type (WT) receptor. Further analysis of one of these mutants in the psoriasis mouse model showed a significant inhibition of psoriasis plaque formation that is similar to the effect of dexamethasone, highlighting the potential of utilizing engineered soluble IL-17RA as drug candidate for autoimmune diseases.
RESULTS

Generation of IL-17RA-ECD Gene Libraries
The IL-17RA receptor is a type I transmembrane protein containing an N-terminal signal peptide, followed by a 291-amino acid (aa) long ECD, a 21-aa long transmembrane domain, and a 521-aa long cytoplasmic tail (Yao et al., 1997) . We cloned the full length ECD of the receptor, consisting of 291 residues, as a first step in the generation of IL-17RA mutant library. Next, we used multiple sequence alignment of IL-17RA ECD to generate a focused back-to-consensus IL-17RA library ( Figure S2 ) (Berger et al., 2011; Lehmann and Wyss, 2001) . In recent years, several approaches have been developed to generate small and functionally rich gene libraries based on the structure, function and evolution of the target protein (Lutz, 2010) . One of these approaches is by targeted mutagenesis of residues that deviate from the consensus sequence of the gene family to generate a back-to-consensus library (Amar et al., 2012; Berger et al., 2011; Lehmann and Wyss, 2001 ). This library approach was shown to enhance the stability and activity of the target protein (Bershtein et al., 2008; Bloom et al., 2006) .To identify target residues that deviate from the family consensus in the IL-17RA ECD, six mammalian IL-17RA sequences were aligned. We identified 16 different positions that deviate from the IL-17RA family consensus (Table S1 ). To generate a IL-17RA gene library containing back-to-consensus mutations, we adapted a recently developed methodology termed ISOR (incorporation of synthetic nucleotide via gene reassembly) (Herman and Tawfik, 2007) for partial mutagenesis of the targeted positions. This methodology is an adaptation of gene shuffling and allows simultaneous diversification of specific residues by spiking with synthetic oligonucleotides containing the desired mutations during the gene assembly process (Stemmer, 1994) (Figure S2B ). Following library generation, sequencing of 14 random IL-17RA library variants indicated an insertion of two to seven back-toconsensus mutations per gene with an average of four mutations per gene. Each library variant carried a random and different subset of mutated residues (data not shown). The complexity of the library, given an average insertion of four back-toconsensus mutations per gene, is $20,000 mutants.
Enrichment of the IL-17RA Library Using Yeast Surface Display YSD is a powerful method for engineering proteins with increased affinity, specificity, and stability (Chao et al., 2006) . The YSD approach provides several advantages over other methods for high-throughput screening of large mutant libraries. This approach enables quantitative screening of large libraries through the use of fluorescence-activated cell sorting, allowing the real-time analysis of the library characteristics and finetuning of the selection threshold (Chao et al., 2006) . We have utilized the YSD approach to display the IL-17RA on the yeast cell surface and to examine its binding to IL-17A (Figure 1 ). The display level of IL-17RA was monitored using fluorescein isothiocyanate (FITC)-labeled antibodies against the myc tag introduced at the C terminus of the protein. Binding to IL-17A was monitored using biotinylated a-IL-17A antibodies followed by incubation with streptavidin conjugated to allophycocyanin (APC). We found that the WT IL-17RA is displayed on the yeast cell surface at low levels, relative to the proliferating cell nuclear antigen (PCNA) protein from Saccharomyces cerevisiae expressed under identical conditions (Fridman et al., 2010) (Figure 1B) . To enrich the naive library for mutants with enhanced display levels and affinity to IL-17A, yeast cells displaying the IL-17RA library were incubated with IL-17A and more than 5 3 10 6 cells were analyzed and sorted by fluorescence-activated cell sorting (FACS) based on a fluorescence expression and binding signal. Two iterative rounds of enrichment were performed leading to a continuous increase in the mean fluorescence of the population ( Figures 1C and 1D ). In parallel, we have generated and examined random mutagenesis library of IL-17R containing two to six random mutations using YSD followed by FACS sorting. We found that the random mutagenesis IL-17R library did not exhibit significant enrichment for active clones following two rounds of FACS sorting, highlighting the lower frequency of active clones relative to the back-toconsensus library ( Figure S3 ).
Screening of the Enriched IL-17RA Library Using ELISA To identify single IL-17RA mutants with enhanced expression and/or binding affinity for IL-17A, the FACS-enriched library was subcloned into a bacterial plasmid, overexpressed in Escherichia coli, and screened by ELISA. To facilitate the screening of a large number of E. coli extracts containing IL-17RA mutants, we developed a fast and sensitive ELISA for the detection of IL-17RA-IL-17A interaction ( Figure S4 ). The assay is based on immobilizing IL-17A on multiwell plates and detecting IL-17RA binding using specific antibodies. To examine the dynamic range for detection of the IL-17RA-IL-17A interaction, we varied the concentrations of the IL-17RA applied to the plate and found that the assay is highly sensitive and can detect a large range of IL-17RA concentrations ( Figure S4B ). Using this assay, the crude cell lysates of 90 IL-17RA mutants from the FACS-enriched library were screened for binding to IL-17A. The naive library was also directly subcloned into a bacterial plasmid, overexpressed in E. coli, and screened by ELISA. Comparison of the two screening experiments clearly indicates that library enrichment using YSD substantially increased the number of positive clones by a factor of four, relative to the naive library screened without pre-enrichment steps (Table S2) . Overall, the first round of evolution using YSD and E. coli expression systems yielded 22 mutants with increased binding signal relative to the WT IL-17RA (Table S3) .
Mammalian Cell Expression and Characterization of Ten Selected IL-17RA Mutants Recombinant proteins expressed and purified from E. coli lack posttranslational modifications that would occur using mammalian expression systems (Durocher et al., 2002) . It was previously shown that the extracellular domain of many receptors is highly glycosylated and that such glycosylation can significantly contribute to receptor conformation and binding to the target ligand (Tootle and Rebay, 2005) . Indeed, we found that the mobility of the ECD domain of IL-17RA on SDS-PAGE reflects that of a protein with a much higher molecular weight than predicted based on the amino acid sequence ( Figure S5 ). We thus decided to express and purify ten of the IL-17RA mutants from the back-to-consensus library in mammalian cells (V1-V10, Table S1 . recombinant proteins were highly pure (>95%-98%) and contained low amounts of lipopolysaccharide (LPS) suitable for testing in human cell line (Table S4 ). Next, we characterized the ability of the different variants, expressed and purified from mammalian cells, to bind IL-17A using ELISA. We found that two variants, V3 and V10, showed higher binding, relative to WT IL-17RA expressed and purified under identical conditions ( Figure S6 ). To quantitatively characterize the IL-17A binding affinity to V3, V10, and WT IL-17RA, we measured the association and dissociation rate constants between these proteins using surface plasmon resonance (Table 1) . We found that the affinity of the WT IL-17RA to IL-17A is 2.6 nM, a value that is in excellent agreement with the previously reported IL-17A binding affinity (Ely et al., 2009; Wright et al., 2008) . Interestingly, we found that V3 and V10 exhibit 6-and 4-fold increased IL-17A binding affinity, respectively, relative to WT IL-17RA (Table 1) .
Stability of the IL-17RA Mutants
To examine whether the back-to-consensus mutations in V3 and V10, expressed in mammalian cells, affect the thermostability of the proteins, we examined the residual activity of these mutants following incubation at high temperatures, relative to the WT protein. We thus incubated V3, V10, and WT IL-17RA for 30 min at different temperatures, ranging from 37 C to 70 C, and characterized their residual activity using ELISA. We found that incubation of the proteins at temperatures between 37 C and 50 C had no effect on the IL-17RA binding activity. However, we observed a gradual decrease in the WT binding activity at temperatures higher than 50 C, with almost complete loss of activity at $60 C ( Figure 2 ). In contrast, both V3 and V10 variants were highly active following incubation at 60 C and exhibit an increase in temperature of inactivation of $7 C ( Figure 2 ). To further study the stability of the protein in the human serum, we incubated IL-17RA WT, V3, and V10 with human serum for 5 hr at two different temperatures, 37 C and 40 C, and assessed their residual activity using the IL-17A ELISA binding assay. As a control, we incubated the proteins in PBS under identical conditions. We observed a decrease of up to 33% in activity for the WT IL-17RA following incubation at 40 C, relative to PBS ( Figure S7 ). In agreement with the thermostability analysis of the V3 and V10 (Figure 2 ), we observed lower levels of inactivation of these proteins following serum incubation, relative to the IL-17RA. These results show that V3 and V10 exhibit higher stability than the WT protein in the human serum.
Examining the Contribution of the Different Mutations to IL-17A Activity and Thermostability
To examine the contribution of the back-to-consensus mutations identified in V3 and V10 to the activity and thermostability of the proteins, we generated and examined a series of sitedirected mutants. We mutated the majority of the mutations found in V3 and V10 individually back to the WT residue (Table  2) . For example to assess the contribution of the K109R mutation in V3, we generated a V3 variant in which residue R109 is mutated to K, where K is the WT residue at this position. These mutants were expressed in mammalian cells to maintain posttranslational modifications and examined for binding to IL-17A using ELISA. In addition, we examined the thermostability of the active mutants following 30 min of incubation at elevated temperatures and characterized their residual activity using ELISA (as described previously). Detailed analysis of single mutants of the V3 indicated that two backto-consensus mutations, D123G and H156D, are completely essential for IL17-RA binding to IL-17A (Table 2) . Interestingly, we found that R109K mutation results in an $50% decrease in binding to IL-17A but significant decrease in thermostability. Similar analysis of mutations in V10 confirmed the importance of D123G and R109K for IL-17A binding and thermostability, respectively. The V10 analysis also revealed that F60V mutation is crucial for IL-17A binding. Our mutational analysis shows that most of the back-to-consensus mutations are essential to IL-17RA binding and indicates that these mutations cooperatively contribute to IL-17RA activity. However, this analysis suggests that it is possible to reduce the number of mutations in V3 by back mutation of L10P, G244W, and A268V, enabling a decrease in the risk of immunogenicity following administration. Mapping the mutations present in the V3 and V10 mutants on the recently solved crystal structure of WT IL-17RA ECD (Ely et al., 2009) revealed that most of the mutations are scattered on the outer surface of the protein ( Figure S8 ). 
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Cell-Based Assay and In Vivo Analysis of IL-17RA Mutants To examine the ability of the recombinant IL-17RA mutants, expressed in mammalian cells, to inhibit IL-17A binding to the endogenous IL-17RA receptor in cells, we established a cellbased assay to measure the level of IL-17A-induced cytokine secretion. The assay is based on measuring Gro-a and IL-6 secretion following IL-17A addition to human fibroblast cells. The addition of soluble IL-17RA together with IL-17A prevents ligand binding to the endogenous IL-17RA receptor due to competition, thus leading to reduced IL-6 and Gro-a secretion.
We found that addition of increasing concentrations of IL-17RA to the fibroblast cells together with 10 ng/ml IL-17A is sufficient to inhibit IL-17A-induced Gro-a and IL-6 secretion ( Figure S9 ). We found that the inhibition of Gro-a secretion was consistent with the inhibition of IL-6 secretion, indicating a decreased level of IL-17A binding to the endogenous receptor ( Figure S6 ). Next, we tested the ability of the V3 and V10 mutants to inhibit IL-17A-induced Gro-a secretion relative to the WT protein. Both mutants were able to inhibit Gro-a secretion in human fibroblasts at lower concentrations than did the WT protein (Figure 3 ). We found that the presence of V3 and V10 at concentrations of 0.25 and 0.1 mg/ml, respectively, leads to at least 90% inhibition of IL-17A induced Gro-a secretion (Figure 3 ). To further examine the in vivo inhibitory activity of IL-17RA on IL-17A-induced Gro-a secretion in mice, we first calibrated the amount of IL-17A injection and the duration of time that is needed to obtain optimal levels of Gro-a secretion in mice (data not shown). We found an increase of $18 fold in Gro-a levels in blood samples of mice collected 2 hr after IL-17A injection (1.5 mg/kg; Figure 4 ). To validate that the IL-17A indeed leads to elevated levels of Gro-a secretion, we injected IL-17A following pre-incubation with antibody against IL-17A and observed a decrease of $35% in Gro-a secretion levels (Figure 4) . The antibody against IL-17A was used at a relatively low concentration and served as a positive control for verifying the IL-17A induced Gro-a secretion in vivo. Next, IL-17A was injected into mice with or without pre-incubation with WT IL-17RA, or the V3 or V10 mutants. We found that the injection of IL-17A following pre-incubation with WT IL-17RA led to an inhibition of 65% in Gro-a secretion (Figure 4) . Interestingly, pre-incubation of the IL-17A with the V3 or V10 mutant led to inhibition of 70% and 82% in Gro-a secretion, respectively, that is higher than the inhibitory effect observed for the WT protein (Figure 4 ). This result is in excellent correlation with the increased IL-17A binding affinity of these mutants, relative to the WT protein (Table 1) .
In Vivo Analysis of IL-17RA V3 Mutant in the Psoriasis Mouse Model
To assess the therapeutic potential of V3 variant in the recovery of psoriasis lesions, we examined the therapeutic effect of V3, expressed in mammalian cells, in a psoriasis mouse model. To establish such a model, skin samples from psoriasis patients were transplanted into SCID mice and 28 days following skin transplant, IL-17RA V3 was administered via subcutaneous injection twice a week for 4 weeks. We have examined different concentrations of V3 including 3.5, 7, 14, and 28 mg/kg. After 56 days from the initial skin transplant, the mice were sacrificed and the recovery of the psoriasis lesions was assessed histologically. The level of recovery was scored from 1 to 4, where 1 is the psoriasis form, 2 is partial recovery, 3 is partial to complete recovery, and 4 is complete recovery. As expected, we found that there was psoriasis disease present in six of eight of the mice treated with PBS ( Figure 5 ; Table S5 ). Treatment with dexamethasone inhibited disease in six of eight mice, similar to historical data within this model (Nair and Nair, 1975) . We found the administration of 7 mg/kg of V3 led to inhibition of the disease in six of eight mice and the effect was slightly higher than that with dexamethasone, which was used as a positive control ( Figure 5 ; Table S5 ). We found an attenuated response at lower or higher V3 concentrations, highlighting the optimality of 7 mg/kg for the treatment of psoriasis in the mouse model (Figure 5 ; Table S5 ).
DISCUSSION
In this work, we employed a directed evolution approach to generate an improved soluble IL-17RA receptor with increased IL-17A binding affinity, stability, and inhibition of IL-17A-induced secretion of cytokines. The binding of IL-17 to its endogenous Figure 2 for examples).
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Directed Evolution of Soluble Human IL-17 Receptor cell surface receptor was shown to be associated with many inflammatory conditions and autoimmune diseases (Gaffen, 2009 ). Thus, the direct inhibition of IL-17A binding using a soluble receptor can lead to the prevention of inflammatory conditions and may provide beneficial therapeutic effects. Other approaches for direct blocking of IL-17A interaction include the use of antibodies against the IL-17A or IL-17RA. Currently, humanized antibodies for these proteins are in different stages of clinical trial for several conditions, including RA, Crohn diseases, and psoriasis (Kopf et al., 2010) . In contrast, to the best of our knowledge, no soluble IL-17 receptor is in clinical trial despite the high potential of this therapeutic approach for blocking IL-17-induced inflammation. Other indirect approaches that target IL-17A-induced signaling affect upstream or downstream mediators of IL-17A signaling, such as MAP kinases (Laan et al., 2001; Prause et al., 2003) . The use of soluble receptors for blocking ligand-receptor interactions may have unique therapeutic effects in different individual and disease states (Gershoni, 2008; Huang, 2009 ). This approach allows neutralization of the target ligand through native ligand-receptor binding mode in contrast to antibodies that can bind the target ligand through different interaction regions. The first successful example of using a soluble receptor as a therapeutic drug is the TNF-a soluble receptor (Etanercept), which is composed of the soluble ECD of the TNF-a receptor II fused to the Fc domain of the IgG1 (Mohler et al., 1993; Peppel et al., 1991) . This soluble receptor neutralizes both the membranebound and the soluble forms of TNF-a and, therefore reduces the concentration of serum inflammatory cytokines (Mohler et al., 1993; Peppel et al., 1991) . This approach mainly utilizes the WT extracellular domain to trap the target ligand. The ability to engineer soluble receptors for higher ligand binding affinity and stability can increase the potency and applicability of the latter as therapeutic drugs. Indeed, our results indicate that the engineered IL-17RA V3 and V10 mutants exhibit higher IL-17A binding affinity in vitro and increased levels of inhibition of IL-17A-induced Gro-a secretion both in a cell line and in vivo using a mouse model (Figures 3 and 4) . The immediate challenges that still remain until the protein becomes a drug are the validation that mutations that lead to improved ligand binding affinity and stability do not lead to immunogenicity, examination of the pharmacokinetics of the engineered receptor, and further preclinical development. Analysis of potential immunogenicity of the WT IL-17RA, V3, or V10 proteins was performed by searching the protein sequences for known human immune epitopes using the epitope database (http://www.immuneepitope.org/). No human immune epitopes were identified within the IL-17RA,V3, and V10 sequences reducing the risk for immunogenicity of these proteins in humans.
One efficient way for increasing protein function using a directed evolution methodology involves inserting back-toconsensus mutations into the protein sequence for the generation of small and effective gene libraries. Such an approach implements evolutionary information based on sequence alignment and is a modification of the conventional family DNA shuffling process for the generation of gene libraries (Herman and Tawfik, 2007; Bershtein et al., 2008; Bloom et al., 2006) . Indeed, focused IL-17RA library containing different combinations of back-to-consensus mutations contained relatively high percentage of variants exhibiting increased binding following expression in E. coli (Table S2) . We found that pre-enrichment using YSD further reduced the need for extensive screening and increased the number of positive clones for downstream analysis (Table S2) . Previously, consensus and ancestral mutations were systematically studied and found to significantly increase the activity and thermostability of different target proteins (Tokuriki and Tawfik, 2009 ). Mapping of the back-toconsensus mutations identified in V3 and V10 on the IL-17RA crystal structure (Ely et al., 2009 ) reveals that most of these mutations are located on the surface of the receptor ( Figure S8 ). These mutations can probably lead to increased stability and IL-17A binding affinity by minor indirect effects on the conformation and solubility of the IL-17RA mutants. Detailed analysis by sitedirected mutagenesis of the majority of these mutations back to the WT residues (Table 2) indicates the contribution of individual residues to the binding affinity and stability of the V3 and V10 variants. We found that the majority of the back-toconsensus mutations are essential for the activity or thermostability of the variants, indicating a cooperative mode of action of these mutations.
In vivo analysis of the improved IL-17RA mutants indicated that the increase in IL-17A affinity and stability of these mutants Cells were incubated for 24 hr with 10 ng/ml hIL-17A and different concentrations of soluble IL-17RA WT and mutant receptors. The undiluted cell supernatant was analyzed by ELISA for detection of Gro-a levels. The values presented here were calculated following subtraction of the basal Gro-a secretion signal (OD 450 = 0.2). The data represent the average of three independent repeats of each experiment and the error bars represent the standard deviation from the average. See also Figures S5, S6 , S8, and S9 and Table S4. relative to the WT is correlated with an increase in the inhibition of IL-17A-induced cytokine secretion in the mouse model. These results highlight the potential of directed evolution in generating engineered proteins with superior properties in vivo relative to the WT protein. In addition, we found the IL-17RA V3 mutant can effectively promote the recovery of psoriasis lesions in the mouse model. This result is in agreement with the recent success of antibodies against IL-17A or IL-17 receptor in phase 2 clinical trials for the treatment of psoriasis Papp et al., 2012) . The use of a soluble receptor provides a means for IL-17A inhibition that can be complementary to antibodies as a drug candidate for psoriasis. Such an approach provides the advantage of targeting IL-17A at its receptor binding site allowing efficient competition with the endogenous IL-17RA cell surface receptor. In addition, this soluble receptor can be examined in other autoimmune diseases, including Crohn disease and RA. SIGNIFICANCE IL-17 is a proinflammatory cytokine involved in the progression of several common autoimmune diseases, such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Inhibition of IL-17A proinflammatory activity is achieved mainly by antibodies targeting the IL-17A itself or its endogenous receptor. Here, we utilized directed evolution to generate soluble IL-17RA with improved properties for the inhibition of IL-17A binding to its endogenous cell surface receptor. Our results show that engineered IL-17RA exhibiting increased IL-17A binding affinity and stability can inhibit IL-17A-induced cytokine secretion in cell line and in vivo, demonstrating the power of protein engineering for generating proteins with improved in vitro and in vivo activities. Moreover, the ability of the engineered receptor to promote the recovery of psoriasis plaque in mice highlights its potential as a drug candidate for this common autoimmune disease. Targeting IL-17A by the engineered IL-17RA can serve as a complementary approach for existing approaches utilizing antibodies and may efficiently target the precise regions in IL-17A involved in the interaction with its endogenous cell surface receptor. We think that directed evolution can serve as a general approach for the engineering of soluble receptors for increased stability and activity, for the study of ligand-induced cell responses, and as a first step for the generation of a new class of therapeutic agents for a wide range of diseases.
EXPERIMENTAL PROCEDURES Plasmids
The human IL-17RA extracellular domain was amplified from EST cDNA clone of human IL-17RA purchased from Open Biosystems. For E. coli expression, the ECD of the gene was cloned into the pET32 plasmid (Novagen). Cloning was performed using NcoI and NotI sites to yield a thioredoxin (Trx)-6x Histidine-tagged version of the protein. The E. coli Clooni strain (Lucigen) was used for cloning and plasmid extraction. For YSD, the variants were cloned into the pCTCON plasmid using the NheI and BamHI sites (Chao et al., 2006) . For expression in mammalian cells, the pFUSE (Invivogen), pFW02 (CrownBio) and pYD11 (CrownBio) vectors were used to yield IL-17RA-ECD variant fused with human IgG1 Fc to increase the serum half-life of IL-17RA (Huang, 2009) . Primers used for the cloning and library construction are listed in Table S6 .
Yeast Surface Display IL-17RA variants were displayed on the yeast cell surface of EBY100 strain cells (see (Chao et al., 2006) for genotype) and analyzed by flow cytometry, essentially as described (Bloom et al., 2005) . Briefly, EBY100 cells transformed with plasmid pCTCON containing the desired clone were grown in SDCAA media (20 g sucrose, 6.7 g yeast nitrogen base, 5 g casamino acids, 5.4 g Na 2 HPO 4 , and 8.56 g NaH 2 PO 4 3 H 2 O) at 30 C to logarithmic phase. Then, 2 3 10 6 of cells were washed, resuspended in SGCAA induction media (similar to SDCAA but containing galactose instead of sucrose), and grown at 37 C with shaking for an additional 18 hr. Induced cells (1 3 10 6 ) were collected by centrifugation, washed with PBSF (PBS + 1 g/L BSA) and incubated for 1 hr at 25 C with 0.2 mM hIL-17A (R&D Systems). The cells were then washed and incubated for 1 hr at 25 C with mouse a-myc antibodies (Santa Cruz Biotechnology, 1 ml/50 ml PBSF) and goat biotinylated a-hIL-17A (R&D Systems, 0.25 ml/50 ml PBSF). Subsequently, cells were washed again and incubated with FITC-conjugated a-mouse IgG (Sigma, 1 ml/50 ml PBSF) and allophycocyanin-conjugated streptavidin (Jackson Immunoresearch, 1 ml/50 ml PBSF) for an additional hour on ice, with frequent mixing. The labeled cells were washed, resuspended with PBSF, and analyzed by flow cytometry (FACS Calibur, BD). Injection of IL-17A (1.5 mg/kg) into groups of mice (n = 5 in each group) leads to significant increases in Gro-a levels. Pre-incubation of IL-17A with antibody against IL-17A (2 mg/kg), WT IL-17RA, V3, or V10 leads to inhibition of Gro-a secretion. The antibody against IL-17A was used as a positive control for IL-17A-induced Gro-a secretion in vivo. We found that the inhibition of IL-17A-induced Gro-a secretion is significantly higher with the V3 or V10 than the inhibition obtained with WT. All IL-17RA variants were injected at a concentration of 14 mg/kg and Gro-a levels were analyzed in blood samples collected 2 hr after injection (see Experimental Procedures for detailed description). The data represent the average of five independent measurements (five mice in each group) and the error bars represent the standard deviation from the average. See also Figures S7 and S8.
Library Generation
For the generation of IL-17RA back-to-consensus library, the human IL-17RA gene was amplified by PCR, and $10 mg were digested with DNaseI to yield 50-125 bp fragments, as previously described (Stemmer, 1994) . The fragments were reassembled, as in DNA shuffling (Aharoni et al., 2004) , in the presence of a mixture of 18 short oligonucleotides (4-6 nM each, Table S5) , resulting in a library containing two to seven mutations in each gene with an average number of four mutations (Aharoni et al., 2004; Stemmer, 1994) . The estimated complexity of the library is $20,000 mutants based on the following equation: N!/(N-K)! 3 K, where N is the total number of positions (18) and K is the average number of mutations inserted into the gene (four). The reaction mixture was further amplified by nested PCR, as described (Chao et al., 2006) . The assembled libraries were ligated into the pET32 vector for E. coli expression and into the pCTCON vector for YSD. Error-prone libraries were generated with mutagenic dNTP analogs, 8-oxodG and dPTP (Zaccolo et al., 1996) , and two to six mutations per gene were obtained. The library was then ligated into the pCTCON vector for YSD.
Library Selection Using Yeast Surface Display
The naive library was induced and labeled with c-myc and IL-17A, as described above. EBY100 cells (1 3 10 7 ) displaying the IL-17RA library were labeled, analyzed, and sorted using a FACS (Vantage, BD). Two iterative rounds of enrichment were performed. In each round, multiple positive events (3-5 3 10 4 ), corresponding to cells found within the top 1%-2% of the green and red fluorescence intensity area, were collected into growth media and plated on agar for a new round of enrichment. For initial sorting of the naive library, a sorting gate of the top 5% of fluorescent cells was used. Selection rounds were continued until no further enrichment was obtained.
Cloning and Bacterial Expression of IL-17RA-ECD Variants
A pool of plasmids from the last round of FACS enrichment was PCR-amplified, cloned into plasmid pET32 and transformed into the E. coli BL21 (DE3) strain (Novagen). In parallel, the naive library was directly cloned into pET32 plasmid and transformed into the E. coli BL21. Following transformation, single colonies were inoculated into 10 ml LB media containing 100 mg/ml ampicillin, grown to OD 600 of 0.6, and induced with 1 mM of IPTG (Calbiochem) overnight at 30 C. The cells were then harvested; lysed in PBS supplemented with 0.2% Triton, 200 mg/ml lysozyme (Calbiochem), and 10 mM b-mercaptoethanol; centrifuged; and the cleared supernatant was collected and analyzed with ELISA (see below). We screened 180 mutants from the naive library and 90 mutants from the FACS-enriched library to identify clones with improved activity relative to the WT protein.
Protein Expression in Mammalian Cells
For large-scale purification of IL-17RA variants, HEK293F cells were transiently transformed with 1 mg/ml of DNA at a DNA/PEI ratio of 1:3 or 1:4, and harvested after 6-7 days. The recombinant proteins were purified on a HiTrap Protein A HP column, with 20 mM sodium phosphate, pH 7.0, as binding buffer and 100 mM sodium citrate, pH 3.0, as elution buffer. The proteins were then analyzed by silver stain and western blot using specific antibodies against the Fc, following SDS-PAGE. Purified proteins were stored at À80 C in 50 mM
Tris, 200 mM NaCl, pH 7.5, until further analysis.
ELISA Assay for IL-17A Binding ELISA plates (Griener Microlon 96W) were incubated with 100 ml of 0.5 mg/ml goat a-hIL-17A antibodies (R&D Systems) for 1 hr, washed with PBS supplemented with 0.05% Tween-80 (PBST), and 100 ml of 0.35 mg/ml IL-17A (R&D Systems or ProSpec Tany TechnoGene) were added to the plate for an additional hour. The plates were then washed with PBST and blocked by incubation with 100 ml of PBS supplemented with 3% skim milk for 1 hr. Following blocking, the plates were washed and incubated with 100 ml of the cleared lysate, cell media or purified protein, and shaken for 1 hr. IL-17RA (R&D Systems) was added at a concentration of 6.25 mg/ml as a positive control, and PBS supplemented with 1% BSA served as a negative control. Plates were then washed with PBST, incubated with 100 ml of 0.05 mg/ml goat a-hIL-17RA antibodies (R&D Systems), followed by incubation with secondary peroxidase-conjugated streptavidin (Jackson, 1:10000 dilution). Finally, 100 ml of horseradish peroxidase (HRP) chromogenic 3,3 0 ,5,5 0 -tetramethylbenzidine (TMB) substrate solution (Dako) were added. The reaction was stopped by the addition of 1 M sulfuric acid and recorded at 450 nm using a Tecan Infinite M200 plate reader.
ELISA Assay for the Detection of IL-17RA Expression in E. coli ELISA plates (Griener Microlon 96W) were coated with 100 ml of 0.2 mg/ml streptavidin (Pierce) and 100 ml of 0.05 mg/ml goat a-hIL-17RA antibodies (R&D Systems). The plates were then blocked by incubation with PBS supplemented with 3% skim milk for 1 hr. Next, 100 ml of the cleared lysates were added to each well and the plates were incubated with shaking for 1 hr at room temperature. The plates were washed with PBST and incubated with 100 ml of mouse a-6xHis-tag antibodies (Santa Cruz Biotechnology, 1:2000 dilution), washed with PBST and further incubated with secondary HRP-conjugated goat a-mouse antibodies (Jackson, 1:5000 dilution) for 1 hr. Finally, the HRP chromogenic TMB substrate solution (Dako) was added and the reaction was stopped by the addition of 100 ml of 1 M sulfuric acid and recorded at 450 nm using a Tecan Infinite M200 plate reader.
Protein Thermostability
For protein thermostability tests, the purified proteins and commercially available IL-17RA were diluted in PBS with 1% BSA to a final concentration of 5 mg/ml. The variants were then incubated for 30 min at different temperatures (ranging from 37 C to 70 C). The reaction was terminated by transferring the proteins to liquid nitrogen; the proteins were kept at À80 C and then tested for their IL-17A binding activity with ELISA at room temperature. The residual binding signal was fitted to logistic equation using Sigma plot software. Protein stability of the different variants was also studied following incubation with human serum (Sigma), and compared to that in PBS with 1% BSA. The A dose response for V3 activity is observed between 3.5 and 7 mg/kg; attenuated activity at higher doses was observed. Doses were administered via subcutaneous injection twice a week for 4 weeks in the psoriasis model at concentrations of 3.5, 7, 14, and 28 mg/kg. The data represent the average of eight independent measurements (eight mice in each group) and the error bars represent the standard deviation from the average. See also Figure S7 and Table S5 .
proteins were diluted in serum or PBS to a final concentration of 5 mg/ml, incubated at 37 C and 40 C for 5 hr, and then tested for their IL-17A binding activity with ELISA.
Affinity Measurements Using Surface Plasmon Resonance
The affinity of IL-17A binding to IL-17RA variants was determined by surface plasmon resonance (SPR) measurements on a ProteOn XPR36 (Bio-Rad) instrument. All samples were in HBST buffer (10 mM HEPES with 0.15 M NaCl, 3.4 mM EDTA, and 0.005% Tween-20, pH 7.2). A GLC Chip was airinitialized and activated with EDC/S-NHS. Four micrograms from each of the IL-17RA variants were diluted in acetate buffer, pH 5.5, and immobilized onto the chip. After blocking available unbound sites on the chip with ethanolamine, the chip was washed with HBST buffer and rotated. IL-17A was run at 25 ml/min for 300 s at various concentrations (50, 25, 12.5, 6 .25, and 3.125 nM), followed by a 10-min dissociation step. Binding parameters were determined with the Langmuir single binding site model, using the Bio-Rad's proteOn Manager software V2.1.2.05.
Fibroblast-Based Assay for the Inhibition of IL-17-Induced IL-6 and Gro-a Secretion The normal human skin fibroblast cell line, ATCC CRL2091, was used for the assay. Cells were routinely maintained in completed MEM medium at 37 C with 5% CO 2 . Cell cultures for each experiment were allowed to reach 95%-100% confluence, counted and checked for viability with 0.5% Trypan blue solution (Biological Industries). Cells were then diluted to reach 10 5 cells/ml density, and 100 ml of the cell suspension were added to each well of 96 well plates (Nunc) to obtain 10 4 cells/well. The plates were incubated at 37 C in 5% CO 2 for 24 hr until 95%-100% confluency, and then stimulated for an additional 24 hr with 10 ng/ml IL-17A in the presence or absence of different amounts of the IL-17RA variants. Dose response of the cell lines to IL-17A was tested in each experiment by adding different amounts of IL-17A (from 0 to 20 ng/ml). Cell culture supernatants were then collected and stored at À20 C until further analysis. Measurement of IL-6 and Gro-a in culture supernatants were performed through the use of ELISA kits (R&D Systems or PeproTech) according to manufacturer description.
In Vivo Experiments in Mice
Animal housing and care conditions were maintained according to Teva Pharmaceuticals guidelines, and approved by Teva Pharmaceuticals committee on animal use. Animal welfare was ensured during management, treatment and sampling according to Israeli laws and regulations. At the end of studies animals were sacrificed by CO 2 asphyxiation. The number of the approved application of the ethics committee for animal experimentation is IL-013-02-2003. C57Bl female 8-week-old mice were put in quarantine for 3 weeks. At the age of 11 weeks, the mice were divided into treatment groups (five mice per group). The IL-17RA variants (14 mg/kg, CrownBio), antibody against IL-17A (2 mg/kg, R&D), or PBS were pre-incubated for 20 min at room temperature with human IL-17 (1.5 mg/kg, PeproTech). Treatment involved two subcutaneous injections at the flank area of the conjugate (400 ml/mouse). Two hours post-injection, the mice were euthanized with isofluran and bled from the orbital sinus. The bleeding was terminal and the mice were sacrificed by cervical dislocation. The blood was centrifuged and sera were separated and tested for the level of Gro-a using a Gro-a ELISA kit (R&D) according to manufacturer's instructions.
Examination of IL17RA in Psoriasis Mouse Model
For the psoriasis mouse model study, C.B-17/IcrHsd-scid-bg (SCID) mice (Harlan Laboratories) at 2-3 months of age were used. Healthy human skin pieces at a width of 0.4 mm and surface of 3 3 3 cm, were provided from residual skin of plastic procedures from healthy nonpsoriatic donors (the Plastic Department of the Rambam Medical Center, Haifa, Israel). Skin from a single healthy donor was transplanted onto 48 mice divided into six groups (each group consist of eight mice). For the isolation of peripheral blood mononuclear cells (PBMC) from psoriatic patients, blood samples from eight patients were taken at a volume of 20 ml/patient. PBMC were isolated from these samples by ficoll gradient (Pharmacia) and cultured with 100 U of IL-2 per milliliter (Pepro Tech Inc, Rocky Hill, NJ) in medium composed of RPMI 1640, 10% human AB serum (Sigma, St. Louis, MO), 1% glutamine, and 1%
antibiotics (media components; Biological Industries, Kibbutz Beit Haemeck, Israel). After 14 days, the cells were injected into the human skin explants on the SCID mice. Natural killer (NK) cells from a single patient were suspended in complete medium (RPMI 1640, 10 human AB serum, 1% glutamine, 1% antibiotics, 100 U IL-2 per milliliter), at 10 6 cells per ml and injected into one mouse in each group so that the treatment groups were homogenous (Gilhar et al., 2002) . Treatment groups were as follows: PBS-treated group was a negative control (40 ml/mouse of PBS) from day 42 after skin transplant; dexamethasone-treated group was a positive control (40 ml/mouse of Dexa, 50 mg/ml in PBS, 2 mg/mouse) from day 42 and administration of IL-17RA V3 at concentrations of 3.5 mg/kg, 7 mg/kg, 14 mg/kg, and 28 mg/kg biweekly from day 28. Four weeks after onset of treatment, the skin was harvested. At this stage, skin grafts were blinded, given a code, and analyzed histologically in a blinded fashion. Histologic assessment of the grafts was performed by light microscopy and epidermal thickness was determined with an ocular micrometer. The severity of psoriatic form is scored on a scale of 1-4 by histology, where 1 is the psoriasis form, 2 is partial recovery, 3 is partial to complete recovery, and 4 is complete recovery.
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